EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies

Thijs S. Rietveld, A. Charlotte M.T. de Wolf, Tineke van den Hoorn

Molecular Therapy Advances · 2026-11 · 201895

DOI: 10.1016/j.omta.2026.201895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-11. Verfasst von Thijs S. Rietveld und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Rietveld, T. S., Wolf, A. C. M. D., & Hoorn, T. V. D. (2026). Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies. Molecular Therapy Advances, 201895. https://doi.org/10.1016/j.omta.2026.201895

Vancouver

Rietveld TS, Wolf ACMD, Hoorn TVD. Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies. Molecular Therapy Advances. 2026:201895. doi:10.1016/j.omta.2026.201895

BibTeX
@article{Rietveld2026,
  author = {Rietveld, Thijs S. and Wolf, A. Charlotte M.T. de and Hoorn, Tineke van den},
  title = {Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies},
  journal = {Molecular Therapy Advances},
  year = {2026},
  pages = {201895},
  doi = {10.1016/j.omta.2026.201895}
}
Kostenlos starten →